摘要
目的评估艾塞那肽联合二甲双胍治疗新诊断超重或肥胖2型糖尿病(T2DM)患者的疗效及安全性,以及停用艾塞那肽12周后患者各项指标的变化。方法选取新诊断超重或肥胖T2DM患者50例为研究对象,检测治疗前及艾塞那肽联合二甲双胍治疗12周后患者体重、血糖、C肽、胰岛素、脂联素、C反应蛋白(CRP)、肿瘤坏死因子(TNF-α)及抵抗素以及其他血液生化指标,而后停用艾塞那肽12周,再重复检测上述指标。结果艾塞那肽联合二甲双胍治疗改善了患者胰岛素抵抗和分泌功能,有效降低患者血糖(P<0.01),安全性好,低血糖发生率低,同时可减轻患者体重(P<0.01),升高患者脂联素水平(P<0.05),降低CRP(P<0.05)、TNF-α(P<0.01)及抵抗素水平(P<0.05)。即使停用艾塞那肽12周,患者体重也没有明显反弹(P>0.05),除血糖较前稍升高外(P<0.01),其余指标无显著变化。结论对新诊断超重或肥胖T2DM患者,艾塞那肽联合二甲双胍是安全、有效、优化的治疗方案,并且对患者体重及胰岛素抵抗的改善可产生一定的后续效应。
Objective Objective This study evaluates the efficacy and safety of combination of Exenatide and metformin in the treatment of newly-diagnosed type 2 diabetic patients with overweight or obesity,and the change of indicators in patients after 12 weeks of withdrawal of Exenatide.Methods50 overweight or obese patients were chosen to detect body weight,blood glucose,C-peptide,Insulin,adiponectin,C-reactive protein,Tumor Necrosis Factor-а,resistin and other biochemical markers in blood before and 12 weeks after treatment.Detection were also repeated after 12 weeks of Exenatide withdrawal.ResultsInsulin resistance and secreting function were well-improved with the treatment of Exenatide and metformin.Blood glucose was reduced effectively and safely with low incidence of hypoglycemia（P〈0.01）.at the same time,weight loss（P〈0.01）,increase of adiponectin（P〈0.05）,decrease of CRP（P〈0.05）,TNF-α（P〈0.01）and resistin（P〈0.05） were also displayed during observation.There was no obvious weight regain or changes in other indicators even after 12 weeks of Exenatide withdrawal except a slight rise in blood glucose（P〈0.01）.ConclusionThe combination of Exenatide and Metformin is a safe,effective and optimized treatment for type 2 diabetic patients that are either overweight or obese.It also demonstrates legacy effects on weight management and improvement of insulin resistance.
出处
《中南医学科学杂志》
CAS
2017年第4期369-373,共5页
Medical Science Journal of Central South China
基金
海南省重点科技计划项目资助ZDXM20120046
